ClinicalTrialsFinder
RecruitingNCT05933876

The Impact of Radiotherapy on Oligometastatic Cancer

Stereotactic ABlative Radiotherapy (SABR) in Oligometastatic Cancer (OC): a Radiomics, Multi-omics, and Machine Learning Approach to Clinical Decision-making. the OC-SABR Multicentric Project

Sponsor

Institut Investigacio Sanitaria Pere Virgili

Enrollment

2,000 participants

Start Date

Dec 1, 2022

Study Type

OBSERVATIONAL

Conditions

Metastatic Breast CancerMetastatic Lung CancerMetastasisMetastatic Colorectal CancerMetastatic Prostate Cancer

Summary

Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining whether radiation therapy aimed at a small number of metastases (cancer spots that have spread from the original tumor, called oligometastatic disease) can improve outcomes in patients with breast, prostate, lung, or colorectal cancer. **You may be eligible if...** - You are 18 or older - You have been diagnosed with breast, prostate, lung, or colorectal cancer - You have up to five metastases in the bone, lung, lymph nodes, liver, or brain - You are in good physical condition (ECOG performance status 0 or 1) **You may NOT be eligible if...** - You have non-melanoma skin cancer - You have already received radiation to the same location - You have vascular collagen disease (a connective tissue disorder) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTTo propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR).

Analyze clinical data, medical images and molecular circulating features to propose which variables serve to select the patients that will achieve complete response after SABR.

DIAGNOSTIC_TESTTo propose a diagnostic test to determine the effectiveness of SABR.

Collect blood samples at five different time points before and after treatment and analyze circulating tumoral DNA, medical images, and metabolites to monitor the effect of SABR and its effectiveness.

DIAGNOSTIC_TESTTo propose a diagnostic test for Oligometastatic Cancer (OC).

Analyze circulating tumoral DNA and metabolites from blood samples in search of the profile of OC.

Locations(21)

Complejo Hospitalario Universitario Albacete

Albacete, Albacete, Spain

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Barcelona, Barcelona, Spain

Hospital Universitari Vall d'Hebron

Barcelona, Barcelona, Spain

Institut Català d'Oncologia

Barcelona, Barcelona, Spain

Hospital Universitario Virgen de las Nieves

Granada, Granada, Spain

Hospital Universitari Arnau de Vilanova

Lleida, Lleida, Spain

Hospital de La Luz

Madrid, Madrid, Spain

Hospital Ruber Internacional

Madrid, Madrid, Spain

Hospital Universitario HM Sanchinarro

Madrid, Madrid, Spain

Hospital Universitario Quirónsalud

Madrid, Madrid, Spain

Hospital Universitario Rey Juan Carlos

Madrid, Madrid, Spain

Hospital Universitario Virgen Macarena

Seville, Sevilla, Spain

Hospital Universitari Sant Joan de Reus

Reus, Tarragona, Spain

Hospital Clínico Universitario de Valencia

Valencia, Valencia, Spain

Hospital General Univesitario de Valencia

Valencia, Valencia, Spain

Hospital Universitari Miguel Servet

Zaragoza, Zaragoza, Spain

Hospital del Mar

Barcelona, Spain

Hospital Provincial de Castellón

Castellon, Spain

Institut Català d'Oncologia

Girona, Spain

Hospital Universitario Ramón y Cajal

Madrid, Spain

Hospital de Terrassa

Terrassa, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05933876

Related Trials

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

NCT061494811 location

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239192 locations

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

NCT011741211 location

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357108 locations

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

NCT060606139 locations